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The way in which estrogen receptor α (ERα) mediates gene transcription and hormone-dependent cancer cell
proliferation is now being largely reconsidered in view of several recent discoveries. ERα-mediated transcription
appears to be a cyclic and transient process where the proteasome - and thus receptor degradation - plays
a pivotal role. In view of our recent investigations, which demonstrate the estrogenic activity of a synthetic
peptide corresponding to a regulatory motif of the receptor (ERα17p), we propose that ERα proteasomal
degradation could induce the emergence of regulatory peptide(s).The latter would function as a signal and
contribute to the ERα activation process, amplifying the initial hormonal stimulation and giving rise to sustained
estrogenic response.
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Introduction
Estrogen receptor α (ERα) is commonly depicted as a
transcription factor which, once bound to the appropriate
hormone (e.g., 17β-estradiol; E2), alters the expression
of target genes. However, in view of discoveries made
over the last decade, this simplistic concept must be
reconsidered since the transcription of estrogen-regulated
genes is actually a transient and cyclic mechanism
involving successive recruitments and dissociations of a
large number of corepressors and coactivators (see
[Metivier et al., 2006] for review).These coregulators,
which modulate ERα activity to the same extent as
cognate ligands, should not be viewed as "accessory
proteins", but rather as products of particular genes,
historically called "master genes" [Britten and Davidson,
1969; O'Malley, 2006], that orchestrate coherent and
synchronized events (see [Leclercq et al., 2006] for
review). According to this view, the search for drugs able
to specifically interfere with coregulator recruitment may
open new therapeutic avenues for the treatment of
ERα-related diseases [Galande et al., 2005; Geistlinger
and Guy, 2003; Leduc et al., 2003; Norris et al., 1999;
Rodriguez et al., 2004]. In order to design such
compounds, one must have a clear understanding of the
molecular mechanisms underlying the formation of active
ERα oligomeric structures.
In this Perspective, we describe the regulatory function
of the ERα P295-T311 amino-acid sequence, which harbors
a binding site for calmodulin (CaM) [Gallo et al., 2007a],
a coregulator playing a role of major importance in the
ERα mechanism of action (see [Li and Sacks, 2007] for
review). In addition, we propose that ERα degradation
product(s), including the P295-T311 sequence, may
contribute to the activation process of the receptor.
Link between proliferation and ERα
downregulation
Although involvement of ERα in the growth of
hormone-dependent breast cancers has been clearly
established, ERα expression in primary breast cancers
is generally associated with a favorable prognosis, as
compared to the ERα-negative phenotype. It is noteworthy
that high amounts of ERα are correlated with a low
expression of proliferation markers [Jensen et al., 2001],
clearly indicating an inverse relationship between receptor
level and cell proliferation.
An inverse correlation between ERα stability and
ERE-dependent gene expression has also been reported,
leading to the widely held - albeit subject to controversy
[Alarid et al., 2003; Callige et al., 2005; Fan et al., 2003;
Fan et al., 2004] - concept that the ubiquitin proteasome
system (UPS) contributes to ERα-mediated gene
transcription [Laios et al., 2005; Lonard et al., 2000; Reid
et al., 2003].
www.nursa.org  NRS  | 2008 |  Vol. 6 |  DOI: 10.1621/nrs.06007 | Page 1 of 8
Perspective  Nuclear Receptor Signaling  |  The Open Access Journal of the Nuclear Receptor Signaling AtlasThe ERα P295-T311 sequence is a
regulatory platform
The P295-T311 sequence, located between the D- (hinge)
and E- (Ligand Binding Domain; LBD) domains, appears
to be involved in both the stability and the transcriptional
activity of the receptor.This short sequence, actually
situated in the AF-2a (autonomous activation function)
domain [Norris et al., 1997; Pierrat et al., 1994], can be
considered as a platform for various posttranslational
modifications such as phosphorylation [Lee and Bai, 2002;
Wang et al., 2002], acetylation [Wang et al., 2001],
SUMOylation [Sentis et al., 2005] and monoubiquitination
[Eakin et al., 2007; Heine and Parvin, 2007].This motif
also contains the third nuclear localization signal of the
receptor [Picard et al., 1990;Ylikomi et al., 1992], as well
as a proteolysis site [Seielstad et al., 1995]. Finally, as
stated above, the P295-T311 sequence includes a binding
site for CaM [Bouhoute and Leclercq, 1995; Castoria et
al., 1988; Gallo et al., 2007a; Garcia Pedrero et al., 2002;
Li et al., 2005], a coregulator which enhances both the
transactivation [Biswas et al., 1998; Garcia Pedrero et
al., 2002; Li et al., 2003; Li et al., 2005] and the
stabilization of the receptor [Castoria et al., 1988; Li et
al., 2001] by impeding its E6-AP- (E6-Associated Protein)
mediated polyubiquitination [Li et al., 2006]. It is obvious
that these dual effects do not fit with the concept of a
relationship between ERα-induced transcription and
receptor proteolysis.
In order to further elucidate the role of the P295-T311
segment, we have synthesized a peptide with the same
sequence: ERα17p (P295LMIKRSKKNSLALSLT311).
Surprisingly, this peptide elicits estrogenic responses in
ERα-expressing breast carcinoma cells [Gallo et al., 2008;
Gallo et al., 2007a; Gallo et al., 2007b].Thus, ERα17p
stimulates both cell proliferation and ERE-dependent
transcription.This is associated with receptor
downregulation, occurring through an increase of ERα
degradation rate and a decrease of ERα mRNA level
(Figure 1). Interestingly, it should be stressed that the
latter response is typical of that elicited by agonist ligands.
In spite of the fact that ERα17p binds to CaM and inhibits
its association with ERα, its estrogenic action cannot be
totally ascribed to a CaM-dependent mechanism since
two ERα17p analogs, unable to associate with CaM,
displayed estrogenic properties with a slightly higher
efficiency [Gallo et al., 2007a].
The mechanism by which ERα17p and its analogs
operate is not established as yet, although their
intracellular penetration seems to be required (see below).
In this regard, it should be stressed that ERα, like other
nuclear hormone receptors, is subject to a constant
trafficking between various intracellular compartments
and targets, especially in the absence of (anti)estrogenic
stimulation [Kumar et al., 2006; Leclercq et al., 2006;
Maruvada et al., 2003; Pick et al., 2007; Stenoien et al.,
2000]. Hence, we may logically propose that our peptides
may interfere with this process, as described for
conventional ligands. Note, however, in this context we
do not know if a particular or all forms of ERα (nuclear,
cytoplasmic, membrane-associated, posttranslationally
modified, etc.) are implicated in the mode of action of
ERα17p.
Molecular mechanisms leading to
ERα17p-induced estrogenic effects
Recent investigations from our laboratory have revealed
that ERα17p binds to purified recombinant human ERα
[Gallo et al., 2007b], most likely disrupting intramolecular
interactions suspected to confer upon the receptor an
inactive conformation (i.e., association between the
S305-T311 sequence and the β-turn/H4 composite motif
[Jacquot et al., 2007]).The additional finding that, in
MCF-7 cells, ERα17p dissociates by competition with
ERα-Hsp70 complexes [Gallo et al., 2008], suggests a
complementary mechanism that may contribute to the
agonistic property of the peptide. According to these
observations, we assume that the inactive,
chaperone-stabilized, unliganded ERα adopts a structure
where the hinge region is "closed" by an Hsp70-stabilized
intramolecular interaction between the S305-T311
sequence and the β-turn/H4 motif. Agonist-induced Hsp
dissociation destabilizes this inactive folding, provoking
the "opening" of the hinge with a concomitant exposure
of the P295-T311 motif. CaM, by associating with this motif,
would stabilize the activated ERα oligomeric structure.
This proposal, which of course requires further
experimental validation, could be extended to other
coregulators which modulate molecular interactions
involving the P295-T311 sequence.
Hence, ERα17p and its analogs, regardless of their ability
to interact with CaM, would activate ERα by relieving an
auto-inhibitory folding and provoking concomitantly the
dissociation of Hsp70. Likewise, we assume that CaM
would produce a similar conformational change,
accounting for the antiestrogenic activity of CaM
antagonists.
The ERα P295-T311 motif has a repressive
function
The model outlined above postulates the existence of an
autoinhibitory function associated with the ERα P295-T311
sequence. In support to this view, we and others have
observed that partial or complete deletion of the P295-T311
sequence leads to receptor mutants characterized by a
constitutively high level of transcriptional activity [Gallo
et al., 2007a; Li et al., 2005]. Even in the absence of E2,
these mutated receptors appear unstable, most likely
because of rapid degradation.This could be explained
by their potential inability to establish association with
Hsp70. Interestingly, a motif with a repressive activity has
also been recently localized in the hinge region of the
human androgen receptor (AR) (i.e., R629KLKKLGN636
sequence; Figure 2A) [Haelens et al., 2007], suggesting
that other nuclear receptors may be subject to such
autoregulation.
Genetic arguments support this concept of ERα
autoinhibition. Indeed, a missense point mutation resulting
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Perspective Potential function of peptide(s) derived from ERα degradationFigure 1.  Agonistic properties of ERα. A. Localization of the P295-T311 sequence within ERα. B. MCF-7 cell proliferation. Cells were grown in
the absence (control) or presence of ERα17p at 10 μM or E2 at 0.1 nM taken as a reference. Cell growth was measured by crystal violet staining. C.
ERE-dependent transcription. MVLN cells (MCF-7 cells stably transfected with a pVit-tk-Luc reporter plasmid (Pons et al., 1990) were incubated in the
absence (control) or presence of ERα17p at 10 μM or E2 at 0.1 nM. Luciferase activity, assayed by luminometry, was normalized according to protein
concentration in cell extracts. D. ERα level. MCF-7 cells were cultured in the absence (control) or presence of ERα17p at 1 and 10 μM or E2 at 0.1
nM. ERα and actin levels in cell extracts were determined by Western blot analysis. E. ERα degradation rate. [
35S]methionine labeled MCF-7 cells were
maintained in culture without (control) or with ERα17p at 10 μM or E2 at 1 nM. Immunoprecipitated [
35S]ERα was submitted to SDS-PAGE, revealed
by autofluorography and quantified by measuring band intensities. F. ERα mRNA level. MCF-7 cells were incubated in the absence (control) or presence
of ERα17p at 10 μM or E2 at 0.1 nM. ERα mRNA levels were measured by NASBA (Nucleic Acid Sequence Based Amplification; (Compton, 1991;
Verjat et al., 2004) and normalized according to PPIB mRNA levels. Figures A, B, C and D were adapted from (Gallo et al., 2007a) (Mol Cell Endocrinol
268, 37-49), figures E and F from (Gallo et al., 2008) (J Steroid Biochem Mol Biol, doi:10.1016/j.jsbmb.2007.12.012).
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Perspective Potential function of peptide(s) derived from ERα degradationFigure 2.  Sequence alignment of AR, ERRβ and ERRγ with ERα. A. AR E621-G643 versus ERα P295-T311.The AR inhibitory motif
(R629KLKKLGN636) delineated by Haelens et al. (Haelens et al., 2007) is boxed. B. Orphan receptors ERRβ (C158-A315) and ERRγ (C183-A340)
versus ERα (C240-E419), gaps within the orphan receptor regions corresponding to the C-terminus part of the ERα P295-T311 sequence are boxed.
Sequences were downloaded from the ExPASy Proteomics Server (http://au.expasy.org) (accession numbers: ERα: P03372, AR: P10275, ERRβ:
O95718 and ERRγ: P62508). Alignments were carried out using T-Coffee server (http://tcoffee.vital-it.ch) (Notredame et al., 2000). Hyphens (-) indicate
a one-residue gap, stars (*) notify identical amino acids, colons (:) and full points (.) highlight amino acids that belong to a ‘strong’ and a ‘weak’ group,
respectively.
in a K303R substitution was shown by Fuqua et al. to
increase the sensitivity of the receptor to E2 [Fuqua et
al., 2000; Herynk and Fuqua, 2004].This functional ERα
alteration, which could be explained by a decrease of the
autoinhibition exerted by the P295-T311 sequence, has
been found associated with high tumor grade [Conway
et al., 2005]. On the other hand, according to sequence
alignments (Figure 2B), orphan estrogen receptors
(Estrogen receptor-Related Receptors; especially ERRβ
and γ display a gap in the region corresponding to the
ERα P295-T311 sequence, a characteristic which might
explain the constitutive activity of these receptors.
Hence, one could speculate that drugs which enhance
the repressive action of the P295-T311 sequence may be
of therapeutic interest for the treatment of ERα-related
diseases, especially in cases of antiestrogen resistance.
Is an endogenous production of
ERα17p-like peptides conceivable?
Direct interaction of a ligand with ERα is not an absolute
prerequisite for its proteasomal degradation, as
demonstrated with cells labeled with [
3H] tamoxifen
aziridine ([
3H]TAZ), a partial antiestrogen which reacts
covalently with the hormone binding pocket of ERα (Cys
530) [Harlow et al., 1989; Robertson et al., 1981], blocking
access of other ligands [Borras et al., 1994; Borras et al.,
1996; Katzenellenbogen et al., 1983].Thus, in MCF-7
cells, accumulated ERα covalently liganded with [
3H]TAZ
vanishes upon treatment with conventional ligands, a
property explained by the fact that ligand binding to newly
synthesized receptors generates a signal appropriate for
inducing [
3H]TAZ-ERα degradation [Borras et al., 1996].
Similarly, a small percentage of ligand-bound receptor
generates a response which also affects unliganded
receptors, since very low amounts of E2 (sub-Kd doses)
or short E2 pulses are sufficient to produce optimal
transactivation, as well as the degradation of the whole
receptor pool [El Khissiin et al., 2000; Gyling and
Leclercq, 1988; Otto, 1995]. In fact, such behavior
suggests the existence of (a) molecular signal(s) able to
amplify the cellular response to hormonal stimulation.
Could (a) peptide(s) derived from the hormone-induced
proteasomal processing of ERα constitute such (a)
signal(s), the "missing link" connecting receptor
degradation and transactivation?
In view of the estrogenic activity of ERα17p, one may
reasonably wonder whether there is a physiological,
proteasome-mediated production of peptide(s) with similar
estrogenic properties. Insofar as ERα-dependent
transcription is impeded by inhibitors of proteasome [Laios
et al., 2005; Lonard et al., 2000; Reid et al., 2003], it
seems logical to surmise that ERα breakdown which
accompanies transactivation generates peptide(s) that,
like ERα17p, could be involved in the receptor activation
process (Figure 3). From a general point of view, one
may propose that the UPS not only eliminates misfolded,
damaged or obsolete proteins, but also generates
signaling peptides.
If our hypothesis is correct, pure antiestrogens such as
fulvestrant would not induce the emergence of such
peptide(s) with stimulatory properties.The observation
that the binding of pure antiestrogen causes the receptor
to be processed by other UPS components - as compared
to agonist binding - supports this view. Estrogen- and
pure antiestrogen-induced proteasomal degradation
indeed occur in different cellular compartments: while the
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Perspective Potential function of peptide(s) derived from ERα degradationFigure 3.  Induction of ERα activation/degradation cycles by putative peptides generated by the proteasomal degradation of ERα. In the
absence of hormone, ERα-induced gene transcription is maintained at basal level by a low production of peptides originating from receptor proteasomal
degradation. Agonists enhance the production of such peptides, giving rise to sustained ERα activation/degradation cycles.This enhancing signal
would persist until receptor mRNA depletion.
first takes place in the cytosol, the latter implies a nuclear
proteasome system [Callige et al., 2005; Nonclercq et
al., 2007], suggesting that agonists and antagonists may
generate dissimilar ERα proteolytic profiles. In this regard,
it should be stressed that several ways have been
described by which ERα is polyubiquitinated and thus
tagged for proteasomal degradation.While CHIP
(Carboxyl Terminus of Hsp70-Interacting Protein)
exclusively polyubiquitinates unliganded ERα [Fan et al.,
2005;Tateishi et al., 2004], MDM2 (Murine Double Minute
2) seems to promote both basal and E2-associated ERα
degradation [Duong et al., 2007; Saji et al., 2001]. By
contrast, EFP (Estrogen-responsive Finger Protein) and
E6-AP ubiquitin ligases seem to be good candidates for
the specific processing of agonist-bound receptor [Khan
et al., 2006; Li et al., 2006; Nakajima et al., 2007; Nawaz
et al., 1999].
In summary, we assume that agonist-induced
proteasomal degradation of ERα may generate a positive
feedback loop involving receptor degradation product(s).
In this context, the UPS would not only contribute to
promoter clearance, a step required for initiation and
progression of new transcription cycles [Lonard et al.,
2000; Reid et al., 2003], but also enhance ERα activation.
Even if our hypothesis is only based on indirect evidence,
such a mechanism of response amplification is not
unheard of. Indeed, a peptide (receptorphin)
corresponding to a transmembrane segment of the opioid
receptors has been reported to activate the latter [Kampa
et al., 2001]. Interestingly, these receptors are, like ERα,
subjected to proteasomal degradation under agonist
stimulation [Chaturvedi et al., 2001]. Hence, our
hypothesis could apply not only to ERα and/or other
nuclear receptors, but also to a number of UPS-targeted
proteins. Assessment of function and fate of
proteasome-processed peptides would provide important
information in this regard.
Perspectives
In order to test our hypothesis, we are currently trying to
decipher the peptidome of MCF-7 cells under various
experimental conditions (e.g., treatment with agonists or
pure antiestrogens).To date, studies carried out by using
a classical LC-MS/MS approach have failed to reveal the
presence of ERα17p-like peptides. Such a methodology,
commonly used for detection of easily ionizable peptides
in relatively high amounts, seems to be inappropriate in
our case (hypothetical non-tryptic peptides in low
concentrations).To alleviate this drawback, we have
considered using N-terminal sulfonation because it
facilitates the sequencing of newly formed peptides by
predominantly inducing the formation of y-type ion series
during MS/MS fragmentation. Derivatized peptides will
be separated before analysis by liquid chromatography,
and different ionization/detection methods such as
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Alternatively, affinity chromatography on CaM- or
Hsp70-immobilized matrices could be used to concentrate
peptides of interest from cell extracts and conditioned
culture media. Finally, peptide detection and/or extraction
will also be performed using immunological approaches.
Our hypothesis, if confirmed, brings forth new
perspectives in the ever-evolving field of cell signaling.
In addition, clinical consequences would be considerable
with regard to both diagnosis and therapy. From a
diagnostic point of view, one may indeed speculate that
in estrogen-related diseases such as breast cancers,
these putative peptides would be overexpressed and
perhaps secreted or displayed in association with the
MHC (Major Histocompatibility Complex). In a therapeutic
context, one may conceive the design of specific inhibitors
or anticipate immunotherapeutic strategies.
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